Skip to main content
Premera Blue Cross to cover use of Interpace's thyroid test

Interpace Diagnostics' ThyraMIR test has obtained a positive coverage policy decision from Premera Blue Cross as a test for thyroid nodules considered indeterminate by standard cytopathological analysis. The coverage makes the microRNA gene expression classifier available to over 2 million members of the health plan mostly based in Washington, Alaska and Oregon.

Full Story: